Market Overview

UPDATE: Goldman Sachs Downgrades Diebold to Sell on Relative Valuation, Growth Risk

Share:
Related DBD
Stocks Hitting 52-Week Lows
Earnings Scheduled For February 11, 2016

Goldman Sachs downgraded Diebold (NYSE: DBD) from Neutral to Sell and lowered the price target from $29.00 to $27.00.

Goldman Sachs commented, "On a sector relative basis, we downgrade DBD to Sell from Neutral as we are now more cautious on (1) the company's core ATM demand backdrop as banks focus on controlling expenses in a tough environment; (2) potential share losses in the US regional and Brazil ATM market to NCR where its order growth has shown relative strength; and (3) potential pricing risk from a shift in orders to larger banks."

Diebold closed at $30.77 on Tuesday.

Latest Ratings for DBD

DateFirmActionFromTo
Jan 2016Northcoast ResearchUpgradesNeutralBuy
Sep 2015Imperial CapitalMaintainsIn-line
Sep 2015Imperial Capital

View More Analyst Ratings for DBD
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (DBD)

View Comments and Join the Discussion!